2026年全球肝炎报告——信息表

Situation and response Viral hepatitis is one of the world’s most important public health challenges. HepatitisB virus (HBV) and hepatitis C virus (HCV) continue to cause chronic infection, leading tocirrhosis, liver cancer and over one million premature deaths every year. Although both infections are preventable and treatable, HBV and HCV togetheraccount for more than 95% of mortality from viralhepatitis. In highly endemic areas, most chronic HBV infections occur in children aged under 5 years, either through mother-to-child transmission at birth or horizontal transmission in childhood through person-to-person contact in the presence ofopen cuts and sores. People can also be infected with HBV through exposure to infected blood via needle-stick injuries,tattooing, piercing, sexual contact and sharing of contaminated needles or sharp instruments in health care andcommunity settings or among people who inject drugs. The most common routes of HCV transmission include unsafe injections and medical procedures, unscreened bloodtransfusions, and the sharing of needles and syringes among people who inject drugs. The global burden of viral hepatitis Trends in the globalburden of viralhepatitis 287million peoplewerelivingwith chronic HBV or HCV in 20243% of the global population The global prevalence ofchronicHBV infection in children agedunder 5 years decreased from0.8% in 2015 to 0.6% in 2024. Between 2015 and 2024,thenumber of people living withchronic HBV infection declinedby 7.4%, progress was slowerin high-burden regions withstructural and programmaticchallenges. People living withchronic HBV infection People living withHCV infection 25%arein the WHOEasternMediterraneanRegion... 70%arein the WHOWesternPacific andAfricanRegions... Between 2015 and 2024,thenumber of people living withHCV infection declined by 20%,primarily due to the widespreadadoption of curative treatments,notably following the introductionof a short 12-week course ofdirect-acting antivirals (DAAs)in2015. ...where about5% of thepopulation in the Western Pacificand 5% of the population in theAfrican Regions,have chronicHBV infection ...the only region withmore than 1% of its populationinfected with HCV Mortality Incidence In 2024, viral hepatitis B and C caused1.3milliondeaths worldwide, mostly from liver cirrhosis andcancer,including: In 2024, there were1.8million new HBV and HCVinfections, including: HCV‑related deaths HBV‑related deaths 0.9 millionnew HCVinfections 0.9 million new HBVinfections 1.1 million Between 2015 and 2024,reductions innew infections were as follows: Ten countries accounted for69% of chronicHBV deathsand ten countries accountedfor58% of HCV deaths, showing majorgaps in prevention and care showingprogress withimmunizationand preventionprogrammes HCV‑relateddeaths droppedby 12%mainlydue to effectiveantiviral therapies Eliminating viral hepatitis Testing and treatment HBV infection Coverage ofharm‑reduction servicesremains far belowrecommended levels: 85 countries have surpassed the2030targetof reducing chronic HBVprevalence in children aged under fiveyears to less than 0.1% Global targetof 300 by 2030 35 needles and syringesdistributedper person who inject drugs per year Global progress towards eliminatingviral hepatitis as a public health threatby 2030 is off track, but still achievable Priorities for global and regional action To achieve the 2030 global viral hepatitis elimination targets, there arefive major priorities for global and regional action: Despite the availability of effective diagnostics and medicines, access tocare remains critically limited in many high-burden settings. scaling uptreatment for people with chronic HBV infection,especially in the WHO African and Western Pacific regions;scaling uptreatment for people with HCV infection, especially inthe WHO Eastern Mediterranean Region;improving thecoverage of hepatitis B birth‑dose vaccination,especially in the WHO African Region;improving the coverage ofantiviral prophylaxisfor the preventionof mother-to-child transmission of HBV infection, especially in theWHO African Region; andimproving thesafety of nonmedical injections, in particular throughharm-reduction services for people who inject drugs. Under current trajectories, the global target of a65% reduction inhepatitis‑related deaths by 2030, compared with 2015, will not beachievedwithout rapid scale-up of testing and treatment. The 2030 target of a 95% reduction in new hepatitis B infections requiresa massive improvement in the coverage of hepatitis B birth‑dosevaccination in the African regionand improved coverage of antiviralprophylaxis for prevention of mother-to-child transmission. With sustained political commitment, adequate investment andequitable access to proven interventions, elimination of viralhepatitis as a public health threat by 2030 remains achievable.